Full Press Release Details
CytoSorbents Promotes Vincent J. Capponi
MONMOUTH JUNCTION, N.J., May 4, 2020 -
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing
its CytoSorb blood purification technology to treat cytokine storm and
deadly inflammation in critically-ill and cardiac surgery patients around the world, and its Chief Executive Officer, Dr. Phillip
Chan, MD, PhD, announced the promotion of Chief Operating Officer Vincent J. Capponi to President and COO, effective immediately.
Dr. Phillip Chan, MD, PhD, CEO of CytoSorbents
stated, "I am very pleased to announce the promotion of Vince to President and Chief Operating Officer of CytoSorbents Corporation.
Having worked closely with Vince for over a dozen years, much of the success of CytoSorbents to date is a testament to his many
outstanding contributions in all aspects of the company. In his 18 years with CytoSorbents, he has helped to manage the daily
operations of the company, with a focus on manufacturing, engineering, regulatory, clinical studies, new product development and
research. Vince played a pivotal role in the development and scale-up of the polymer technology from an R&D phase to commercial
production, helped to spearhead the first clinical trial in septic shock patients in Germany, and drove European Union (E.U.)
CE Mark designation for CytoSorb as an extracorporeal cytokine adsorber to treat cytokine storm in many illnesses. He further
expanded market access for CytoSorb by successfully navigating three CE Mark label expansions, including the removal of myoglobin
(rhabdomyolysis), bilirubin (liver dysfunction), and earlier this year, the removal of ticagrelor
during on-pump cardiac surgery, with the goal of reducing costly and potentially fatal perioperative bleeding."
Dr. Chan continued, "Most
recently, Vince was instrumental in executing the regulatory strategy that led to FDA Emergency
Use Authorization (EUA) of CytoSorb in adult, critically-ill, COVID-19 patients with imminent or confirmed
respiratory failure, in defined circumstances, and the recent FDA Breakthrough
Designation for the removal of ticagrelor during on-pump emergent and urgent cardiothoracic surgery. In addition,
his vision and leadership around the commercial production and scale-up of CytoSorb has resulted in economies of scale and
major efficiency improvements in both polymer and device manufacturing, taking blended CytoSorb gross margins from 60% to 80%
in Q4 2019. This has, in turn, enabled us to rapidly respond to the increased need for CytoSorb around the globe during this
COVID-19 pandemic, including here in the U.S. under the EUA."
Dr. Chan concluded, "One of Vince's
greatest strengths stems from his favorite mantra of "plan well, execute brilliantly," which he has proven time and
time again over a career that has spanned three decades in the medical device and pharmaceutical industries. As President and COO,
Vince will continue to oversee the operations of the company, with a strong team reporting to him, but will now focus on the development
of new exciting opportunities for CytoSorb and our other technologies. A trusted colleague, I am confident that Vince will do an
Mr. Vince Capponi stated, "At CytoSorbents,
I have experienced what I believe is a once-in-a-lifetime opportunity: to work with a new product concept and be part of a fantastic
team to transform that idea into a life-saving therapy worldwide. We are just beginning to see the true potential of CytoSorb and
what it could mean for the future of critical care and cardiac surgery. As President and COO, I am honored to have been given this
opportunity and look forward to continuing to work with Phil and the management team, to take on new challenges, help make our
corporate goals a reality, increase the overall value of our company, and most importantly, save lives."
About CytoSorbents Corporation (NASDAQ: CTSO)
Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb
is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber
designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause
massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is
extremely high, yet no effective treatments exist. CytoSorb has been used in more than 80,000 human treatments to date.
CytoSorb has received FDA Emergency Use Authorization in the United States for use in
critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also
been granted FDA Breakthrough Designation for the removal of ticagrelor in a
cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.
CytoSorbents' purification
technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and
other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and
other funding of more than $30 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command
(SOCOM), the U.S. Army, U.S. Special Operations Command (USSOCOM), the U.S. Air Force, Air Force Material Command (USAF/AFMC)
and others. The Company has numerous products under development based upon this unique blood purification technology
protected by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL ,
HemoDefend , VetResQ , K+ontrol , ContrastSorb, DrugSorb, and others. For more information, please visit
the Company's websites at www.cytosorbents.com and www.cytosorb.com
Forward-Looking Statements
This press release includes forward-looking
statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations
and contentions and are not historical facts and typically are identified by use of terms such as "may," "should,"
"could," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential," "continue" and similar words, although some forward-looking statements
are expressed differently. You should be aware that the forward-looking statements in this press release represent management's
current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking
statements. Factors which could cause or contribute to such differences include, but are not limited to, our ability to leverage
designation of CytoSorb as a breakthrough device under the FDA's Breakthrough Devices Program in order to expedite the development,
assessment, and regulatory review of CytoSorb, as well as the risks discussed in our Annual Report on Form 10-K, filed with the
SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested
parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking
statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state
and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update
or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required
under the Federal securities laws.
CytoSorbents Contact:
Investor Relations Contact:
Public Relations Contact:
Rubenstein Public Relations